Press

2019-05-24

INTERIM REPORT FOR THE FIRST QUARTER 2019, 1 January – 31 March 2019

First quarter in brief 1 January – 31 March 2019 Net sales for the period (January to March) amounted to SEK 0.0 million (SEK 0.0 million) R&D costs for the period amounted to SEK 10,2 million (SEK 11,8 million)....

Read More
2019-05-14

Kancera’s research will be highlighted at this year’s largest conference on cardiovascular diseases

Kancera AB (Nasdaq First North: KAN) today announces that the European Society of Cardiology has selected Kancera's research for its "outstanding quality" which will result in an oral presentation as part of the session "Advances in Science - Emerging...

Read More
2019-05-03

Kancera puts forward KAND145 as a new drug candidate

This is a translation of the press release in Swedish Stockholm 2019-05-02 Kancera AB (Nasdaq First North: KAN) today announces that the company is strengthening its project portfolio by nominating KAND145 as a new drug candidate. KAND145 is covered...

Read More
2019-03-06

Year End Report Kancera AB (publ) 1st January – 31st December 2018

This is a translation of the Year End Report in Swedish published February 20th 2019.

Read More
2019-02-09

Kancera reports results from analyses of the Fractalkine system in lymphoma patients’ immune cells

This is a translation of a press release in Swedish 2019-01-29 Kancera AB (Nasdaq First North: KAN) today announces that the results of a study of lymphoma patients' immune cells show that the Fractalkine system is activated in the...

Read More
2019-02-09

Kancera has achieved important intermediate goals prior to the planned start of clinical studies with the drug candidate KAND567

This is a translation from the Swedish press release 2019-01-28 Kancera AB (Nasdaq First North: KAN) today announces that intermediate goals have been achieved prior to the planned start of clinical trials with the drug candidate KAND567 to demonstrate...

Read More
2018-12-03

Kancera gains a strong partner for the further development of their HDAC inhibitors

This is a translation of a pressrelease in Swedish from December 3rd 2018. Kancera AB announced today that the company has entered into an Research and Option agreement with Grünenthal, a leading pharmaceutical company in pain research and management....

Read More
2018-11-23

INTERIM REPORT FOR KANCERA  AB (publ) 1st January – 30th September 2018

PERIOD JAN – SEPTEMBER 2018, AND THIRD QUARTER IN BRIEF • Net sales for the period (January to September) amounted to SEK 0.1 million (SEK 0.1 million) of which the third quarter amounted to SEK 0.1 million (SEK 0.0 million). • R&D...

Read More
2018-11-23

Kancera AB announces that a letter of intent has been signed with US-based private investor

Here follows a translation of a Swedish press release from November 23th 2018. Kancera announces that terms have been prepared for a shareholders' decision on investment in the company by Global Corporate Finance (GCF), New York. The investment, which...

Read More
2018-09-24

Discovery of how Kancera’s PFKFB3 inhibitor acts against cancer published in a reputable scientific journal

Kancera AB today announced that the article entitled "Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination" has been published by researchers from Karolinska Institutet and Kancera AB in the journal Nature Communications1. The article documents the molecular mechanisms...

Read More